"10.1371_journal.ppat.1004818","plos pathogens","2015-04-30T00:00:00Z","Ann E Lin; Federico C Beasley; Joshua Olson; Nadia Keller; Robert A Shalwitz; Thomas J Hannan; Scott J Hultgren; Victor Nizet","Division of Pediatric Pharmacology & Drug Discovery, University of California, San Diego, La Jolla, California, United States of America; Aerpio Therapeutics, Cincinnati, Ohio, United States of America; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri, United States of America; Center for Women’s Infectious Disease Research, Washington University School of Medicine, St. Louis, Missouri, United States of America; Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California, United States of America; Rady Children’s Hospital, San Diego, California, United States of America","Conceived and designed the experiments: AEL FCB VN. Performed the experiments: AEL FCB JO NK. Analyzed the data: AEL FCB TJH SJH VN. Contributed reagents/materials/analysis tools: RAS TJH SJH. Wrote the paper: AEL FCB VN.","RAS is an employee of Aerpio Therapeutics, which has sought to develop AKB-4924 for its immunomodulatory properties in inflammatory bowel disease. This does not alter our adherence to all PLOS policies on sharing data and materials.","2015","04","Ann E Lin","AEL",8,TRUE,3,4,5,3,TRUE,TRUE,FALSE,0,NA,FALSE
